Moderator's view: Biomarkers in glomerular diseases - Translated into patient care or lost in translation?

Nephrology Dialysis Transplantation

Volumn 30, Issue 6, 2015, Pages 899-902

  Ronco, Pierre ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; PHOSPHOLIPASE A2 RECEPTOR; PROTEIN;

ANTIBODY TITER; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE CLASSIFICATION; DISEASE SEVERITY; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; MEASUREMENT PRECISION; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; ULTRASOUND; URINE SEDIMENT; BLOOD; CLASSIFICATION; DIABETIC NEPHROPATHIES; DIAGNOSTIC ERROR; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLOMERULUS; KIDNEY DISEASES; LUPUS NEPHRITIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; DIAGNOSTIC ERRORS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY DISEASES; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; MOLECULAR TARGETED THERAPY;

EID: 84939614224     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv106     Document Type: Review

References (22)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95
2. MacMahon GM, Waikar SS. Biomarkers in Nephrology. Am J Kidney Dis 2013; 62: 165-178
3. st edn. Amsterdam, Netherlands: Academic Press/Elsevier, 2011
4. van den Brand JA, Hofstra JM, Wetzels JF. Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011; 6: 2846-2853
5. Irazabal MV, Eirin A, Lieske J et al. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrol Dial Transplant 2013; 28: 137-146
6. Bazzi C, Rizza V, Olivieri G et al. Tubular reabsorption of high, middle and low molecular weight proteins according to the tubulo-interstitial damage marker N-acetyl-β-D-glucosaminidase in glomerulonephritis. J Nephrol 2014 (epub ahead of print)
7. Fervenza F, De Vriese A. Con: Biomarkers in glomerular diseases : putting the cart before the wheel? Nephrol Dial Transplant 2015; 30: 885-890
8. Herrmann SM, Sethi S, Fervenza FC. Membranous nephropathy: the start of a paradigm shift. Curr Opin Nephrol Hypertens 2012; 21: 203-210
9. Clement LC, Avila-Casado C, Macé C et al. Podocyte-secreted angiopoietinlike-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 2011; 17: 117-122
10. Reiser J, Chapman H. Soluble urokinase-type plasminogen activator receptor in FSGS: stirred but not shaken. J Am Soc Nephrol 2014; 25: 1611-1613
11. Yu CC, Fornoni A, Weins A et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013; 369: 2416-2423
12. Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 2014; 63: S39-S62
13. Brunner HI, Bennett MR, Mina R et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum 2012; 64: 2687-2697
14. Mariani LH, Kretzler M. Pro: 'The usefulness of biomarkers in glomerular diseases'. The problem: moving from syndrome to mechanism-individual patient variability in disease presentation, course and response to therapy. Nephrol Dial Transplant 2015; 30: 892-898
15. Ronco P, Floege J. Ten-year advances in immunopathology of glomerulonephritis: translated into patients' care or lost in translation? Semin Immunopathol 2014; 36: 377-379
16. Stanescu HC, Arcos-Burgos M, Medlar A et al. Risk HLA-DQA1 and PLA (2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364: 616-626
17. Beck LH, Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic MN. N Engl J Med 2009; 361: 11-21
18. Ronco P, Debiec H. Membranous nephropathy: recent pathophysiological advances leading to a paradigm shift in patient's care. Lancet 2015; in press
19. Ruggenenti P, Debiec H, Ruggiero B et al. Anti-PLA2R antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 2014; 25: 1786-1798
20. Tomas NM, Beck LH, Jr, Meyer-Schwesinger C et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014; 371: 2277-2287
21. De Abreu FB, Wells WA, Tsongalis GJ. The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine. Am J Pathol 2013; 183: 1075-1083
22. MolitorisB.A.Urinary biomarkers: Alone are they enough?J Am Soc Nephrol2014ASN.2014111145 (epub ahead of print)